Vivos Therapeutics Inc (NASDAQ:VVOS) announced the results of a recent clinical observational study on the application of Vivos’ Preventive Oral Device, dubbed POD, for treating and preventing migraine headaches.
The company recently acquired the patents and rights for The POD, an FDA 510k-cleared device.
The custom device is worn during sleep to treat Temporomandibular Joint Dysfunction (TMD) and aid in symptoms of TMD such as headaches, facial or neck pain, pain in or around the ear, pain when chewing, painful clicking or popping when opening or closing the jaw, or difficulty opening wide.
The study demonstrated statistically significant results, with 92% of patients reporting that their migraine symptoms completely resolved after treatment completion.
Moreover, the results were maintained during follow-up visits extending from 3 to 28 months after treatment began.
Migraine severity was measured by the validated Migraine Disability Assessment Questionnaire (MIDAS).
Before treatment, patients had an average MIDAS score of 23.96 +/- 21.34, and following treatment had a MIDAS score of 2.58 +/- 4.87, a reduction of 89.2%.
Earlier this year, Vivos Therapeutics received FDA 510(k) clearance for its DNA oral appliance to treat obstructive sleep apnea.
Price Action: VVOS shares are down 2.62% at $0.34 on the last check Monday.
